Cytosorbents Corp (CTSO) stock
Close on Nov 13, 2026Market cap $306.04MP/E –Yield –
Earnings
Cytosorbents's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Cytosorbents's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | $9.70M | +2.1% | -$0.58 | -$0.48 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $9.60M | – | -$0.07 | -$0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | $8.90M | +2.3% | -$0.08 | -$0.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 25, 2026during market hours | $9.20M | – | $0.09 | $0.07 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025during market hours | $9.50M | +1.1% | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025during market hours | $8.70M | -11.2% | -$0.02 | -$0.06 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025during market hours | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | $9.40M | +6.8% | -$0.04 | -$0.08 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024during market hours | $9.90M | +5.3% | -$0.08 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | $9.80M | +4.3% | -$0.12 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 15, 2024after the close | $8.70M | -7.4% | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | $8.80M | +8.6% | -$0.21 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023during market hours | $9.40M | +10.6% | -$0.14 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023during market hours | $9.40M | +8.0% | -$0.17 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023during market hours | $9.40M | -13.0% | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $8.10M | -16.5% | -$0.28 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022during market hours | $8.50M | – | -$0.25 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $8.70M | – | -$0.21 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022during market hours | $10.80M | – | -$0.21 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 13, 2021before the open | $9.70M | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 20, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Cytosorbents guided for has been reported
Guidance vs results
The last range Cytosorbents gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q4 FY2021 | Revenue | $8.90M | $10.80M | Above range |
Guidance history
Every forecast Cytosorbents put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Mar 4, 2025 | product gross margin | Q4 FY2024 | 70% | New |
| Mar 4, 2025 | product revenue (excluding grant income) | Q4 FY2024 | $9.00M – $9.20M | New |
| Mar 4, 2025 | product revenue (excluding grant income) | FY2024 | $35.40M – $35.60M | New |
| Mar 15, 2024 | CytoSorb product gross margins | FY2024 | 75% – 80% | New |
| Nov 9, 2023 | product gross margins | near term | 75% – 80% | – |
| Aug 1, 2023 | product gross margins | FY2023 | 75% – 80% | Reaffirmed |
| May 2, 2023 | product gross margins | FY2023 | 75% – 80% | New |
| Mar 8, 2022 | core product sales | FY2022 | +20% | New |
| Oct 13, 2021 | product revenue | Q4 FY2021 | $8.90M | New |
| Oct 13, 2021 | product revenue | FY2021 | $39.30M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Cytosorbents filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Update
- News
- News
- News
- News
- Results
- News
See a number that looks wrong?